CLINICAL STUDY OF TUBERACTINOMYCIN-N IN PULMONARY TUBERCULOSIS

• Published in: Kekkaku Vol. 48; no. 10; pp. 473 - 479
• Main Authors: DONOMAE, Imasato, FUJITA, Shinnosuke, GOMI, Jiro, HIBINO, Susumu, HORAI, Zenji, ITO, Fumio, IWASAKI, Tatsuro, KAWAMORI, Yuzo, KITAMOTO, Osamu, MAEKAWA, Nobuo, NAGASAWA, Jun, NAKAMURA, Takashi, OKA, Sutemi, SHIMAMURA, Kikuji, SUGIYAMA, Kotaro, SUNAHARA, Shigeichi, TOKUOMI, Haruhiko, YAMAMOTO, Kazuo
• Format: Journal Article
• Language: English; Japanese
• Published: Japan JAPANESE SOCIETY FOR TUBERCULOSIS 01.10.1973
• Subjects: Adult; Aged; Anti-Bacterial Agents - therapeutic use; Antitubercular Agents - therapeutic use; Drug Evaluation; Female; Follow-Up Studies; Humans; Male; Middle Aged; Peptides - therapeutic use; Tuberculosis, Pulmonary - drug therapy
• ISSN: 0022-9776; 1884-2410
• DOI: 10.11400/kekkaku1923.48.10_473

Tuberactinomycin-N (TUM-N) is a peptide antibiotic which has been isolated from the culture filtrate of streptomyces griseoverticillatus var. tuberacticus N6-130. This antibiotic is principally effective against tubercle bacilli and the activity is proved to be almost same as that of viomycin. The cross-resistance is observed between TUM-N and viomycin or capreomycin, however, only one way cross resistance is shown with kanamycin, and TUM-N is effective against kanamycin-resistant bacilli. In the present study, authors have observed the therapeutic effect and the side effects of TUM-N in 88 patients of severe pulmonary tuberculosis with cavities, who were sensitive to viomycin. The duration of TUM-N treatment has been fixed for six months and the antibiotic was administered by intramuscular injections at the dose of 1 gram once daily for the first three months and twice weekly thereafter combined with other antituberculous drugs which had been used orally just prior to TUM-N treatment.